通过通过氨基酸交换调节抗原处理来优化针对性抗原递送的T细胞反应
Ida Laurén1, Alexandros Kostakis2, Martin Lord1
1Department of Pharmacy and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
International journal of biological macromolecules
|March 1, 2026
概括
在抗体结合物中修改标签 (pTag) 会影响稳定性和免疫反应. 像pTagK8L这样的较低亲和度标签在体内减少了T细胞扩张,突出了结合稳定性.
科学领域:
- 生物结合化学 生物结合化学
- 免疫学 免疫学 免疫学
- 药物输送系统 药物输送系统
背景情况:
- 抗体与药物联合体 (ADCs) 提供有针对性的输送,以提高疗效和降低毒性.
- 可适应的药物联结策略利用单链可变片段 (scFv) 和标签 (pTag) 来进行有效载荷加载.
- 设计了pTag变体,以评估它们对结合体稳定性和生物活性的影响.
研究的目的:
- 评估pTag中氨基酸替代对抗体结合体稳定性和生物反应的影响.
- 确定改变的pTag亲和力如何影响免疫细胞增殖和体内T细胞扩张.
主要方法:
- 竞争ELISA用于测量pTag变体 (pTag,pTagK8H,pTagK8L) 的结合亲和力.
- 水凝模型来评估结合稳定性.
- 在体外CD8+和CD4+T细胞增殖试验.
- 在体内T细胞扩张研究.
主要成果:
- 非保守的pTagK8L替代降低了结合亲和力 (IC50下降2.4倍) 和结合物稳定性.
- pTagK8L增加了CD8+ T细胞增殖,但在体外略有降低了CD4+ T细胞增殖.
- 在体内,与pTagK8L相比,原始的pTag显示T细胞扩张明显更高.
结论:
- 结合稳定性对于有效的向传递和免疫激活至关重要.
- 较低的pTag亲和力可能会损害免疫反应,这表明亲和力和稳定性之间的平衡是必要的.
- 这项研究提供了关于优化pTag设计用于抗体结合疗法的见解.
相关概念视频
Antigen Processing Pathways
2.6K
MHC molecules are key players in the immune response, enabling T cells to recognize and respond to specific antigens. They are present on the surface of all nucleated cells in the body and are instrumental in presenting antigens to T cells and activating them. T cells recognize the MHC-antigen complex and initiate an immune response. MHC class I and MHC class II are two main types of MHC molecules, each associated with a distinct antigen processing pathway.
MHC Class I: Presenting Endogenous...
MHC Class I: Presenting Endogenous...
2.6K
T Cell Activation and Clonal Selection
16.7K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
16.7K
Modified-Release Drug Delivery Systems: Site-Targeted
51
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
51
Antigen Presenting Cells
3.8K
The immune system is a complex network of cells and molecules that protects the body from foreign invaders. T cells, a type of white blood cell, play a crucial role in this process. They recognize and attack foreign substances, such as pathogens, that enter the body.
T cells require the help of antigen-presenting cells (APCs), which process foreign antigens into smaller fragments that can be recognized by T cells. These APCs are highly specialized cells that efficiently internalize antigens...
T cells require the help of antigen-presenting cells (APCs), which process foreign antigens into smaller fragments that can be recognized by T cells. These APCs are highly specialized cells that efficiently internalize antigens...
3.8K
Site-Targeted Drug Delivery Systems: Polymeric Carriers
63
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
63
tRNA Activation
23.5K
Aminoacyl-tRNA synthetases are present in both eukaryotes and bacteria. Though eukaryotes have 20 different aminoacyl-tRNA synthetases to couple to 20 amino acids, many bacteria do not have genes for all of these aminoacyl-tRNA synthetases. Despite this, they still use all 20 amino acids to synthesize their proteins. For instance, some bacteria do not have the gene encoding the enzyme that couples glutamine with its partner tRNA. In these organisms, one enzyme adds glutamic acid to all of the...
23.5K


